Autoimmune Monoclonal Antibody Market Forecast Reaching $98.81 Billion by 2029 at 8.4% CAGR
We’ve updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
What Are the Key Projections for the CAGR of the Autoimmune Monoclonal Antibody Market Size From 2025 to 2034?
The market size for autoimmune monoclonal antibody has been rising robustly in the recent past. It is forecasted to increase from $65.83 billion in 2024 to $71.71 billion in 2025 with a compound annual growth rate (CAGR) of 8.7%. The spike during this historic period was due to factors such as the increasing incidence of autoimmune diseases, the escalating use of biologics for treatment, a surge in the understanding of targeted therapies, earlier authorizations for monoclonal antibody drugs, and the expansion of healthcare accessibility in developed nations.
The market size of autoimmune monoclonal antibodies is projected to witness substantial growth in the approaching years, reaching $98.81 billion in 2029 with a compound annual growth rate (CAGR) of 8.4%. The growth within the projected period can be ascribed to the escalated demand for personalized healthcare, increased uptake of biosimilars, proliferating autoimmune therapy clinical trials, an expanding elderly population, and a heightened incidence of chronic immune disorders. The forecast period may illustrate notable trends such as advancements in antibody engineering, the invention of bispecific antibodies, the rising application of artificial intelligence in the field of drug discovery, the incorporation of genomics in devising treatment plans, and innovative drug delivery systems.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24162&type=smp
Which Major Market Drivers Are Expected to Boost the Growth Potential of the Autoimmune Monoclonal Antibody Market?
The growth of the autoimmune monoclonal antibody market is being driven by the escalating demand for biologics. Biologics are medicinal products that are made from living organisms or their components, and they are utilized in the diagnosis, prevention and treatment of diseases. Their growing demand stems from their efficacious treatment of complex conditions such as cancer, autoimmune disorders and genetic diseases, cases in which traditional therapies might not be as successful. Autoimmune monoclonal antibodies facilitate biologic therapies by providing specific immune modulation, making them suitable for managing hyperactive immune responses. They curtail the necessity for broad immunosuppressants through providing accurate treatment, which betters patient results and reduces side effects. For instance, Cardinal Health Inc., an American healthcare company, reported that there were 40 FDA approved biosimilar products in 2023. Out of these, 25 are commercially accessible in the American market. This is an uptick from the 33 biosimilar products of 2022. It can therefore be affirmed that the growing demands for biologics are propelling the autoimmune monoclonal antibody market’s prospering.
Which Key Market Segments Comprise the Autoimmune Monoclonal Antibody Market and Drive Its Revenue Growth?
The autoimmune monoclonal antibody market covered in this report is segmented –
1) By Type: Immunoglobulin G Monoclonal Antibodies, Immunoglobulin M Monoclonal Antibodies, Chimeric Monoclonal Antibodies, Fully Human Monoclonal Antibodies
2) By Route Of Administration: Subcutaneous, Intravenous, Intramuscular
3) By Application: Rheumatoid Arthritis, Multiple Sclerosis, Systemic Lupus Erythematosus, Psoriasis, Inflammatory Bowel Disease
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End User: Hospitals, Outpatient Clinics, Homecare Settings, Research Institutions
Subsegments:
1) By Immunoglobulin G (IgG) Monoclonal Antibodies: Immunoglobulin G1 (IgG1), Immunoglobulin G2 (IgG2), Immunoglobulin G3 (IgG3), Immunoglobulin G4 (IgG4)
2) By Immunoglobulin M (IgM) Monoclonal Antibodies: Pentameric Immunoglobulin M (IgM), Hexameric Immunoglobulin M (IgM)
3) By Chimeric Monoclonal Antibodies: Murine Variable Region + Human Constant Region, Humanized Variable Region + Murine Constant Region
4) By Fully Human Monoclonal Antibodies: Phage Display-Derived, Transgenic Mouse-Derived, Fully Human Hybridoma-Derived
Request customized data on this market:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24162&type=smp
Which Areas Are Leading Regions in the Autoimmune Monoclonal Antibody Market Expansion Across the Globe?
North America was the largest region in the autoimmune monoclonal antibody market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the autoimmune monoclonal antibody market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Key Market Trends in the Autoimmune Monoclonal Antibody Market Over the Coming Years?
Major corporations involved in the autoimmune monoclonal antibody market are dedicating their efforts to creating novel solutions, including the development of biosimilars that prioritize safety, effectiveness, and quality. This development process involves the creation of closely similar, secure, and efficient biological products to pre-approved biologics utilizing modern biotechnology, thorough analytical testing, and clinical trials to showcase similar quality, effectiveness, and safety for regulatory sanctioning. As an example, in February 2025, Biocon Biologics Limited, a biopharmaceutical firm from India, introduced YESINTEK, a biosimilar designed to cure autoimmune ailments such as Crohn’s disease, ulcerative colitis, and psoriasis. YESINTEK does this by targeting and inhibiting the interleukin-12 and interleukin-23 activities to mitigate inflammation and control the immune response. It impersonates the reference product, stelara, meaning it can support long-term disease control, enhancing patient access to biologic therapies.
View the full report here:
How Is the Autoimmune Monoclonal Antibody Market Conceptually Defined?
Autoimmune monoclonal antibodies are lab-made proteins designed to target specific components of the immune system involved in autoimmune diseases. These antibodies help regulate or block abnormal immune responses that mistakenly attack the body’s own tissues. Their main purpose is to reduce inflammation and prevent the immune system from attacking the body’s own tissues, thereby minimizing damage and maintaining normal physiological function.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/customise?id=24162&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
